Dystrophy, Retinal Clinical Trial
Official title:
Brolucizumab-dbll (BEOVU®) Intravitreal Injection in the Treatment of Dystrophy-related Macular Neovascular Degeneration
Dystrophy-Related macular neovascularization degeneration occur is a vision threatening condition.The investigators evaluate the efficacy of BEOVU intravitreal treatment.
Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done. Procedure included intravitreal injection of Brolucizumab (BEOVU®, Genen-tech, South Francisco, CA) ;